Next Article in Journal
Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Relapsed and Refractory Mantle Cell Lymphoma
Previous Article in Journal
The Impact of Seasonal Operating Room Closures on Wait Times for Oral Cancer Surgery
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 1
10.3747/co.25.3867
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Guidelines

Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer

by
B. Melosky
1,*,
N. Blais
2,
P. Cheema
3,
C. Couture
4,
R. Juergens
5,
S. Kamel-Reid
6,
M.-S. Tsao
6,
P. Wheatley-Price
7,
Z. Xu
8 and
D.N. Ionescu
1
1
British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada
2
CHUM, Montreal, QC, Canada
3
William Osler Health System, University of Toronto, Toronto, ON, Canada
4
IUCPQ-Université Laval, Québec City, QC, Canada
5
McMaster University, Juravinski Cancer Centre, Chair of Medical Advisory Committee, Lung Cancer Canada, Hamilton, ON, Canada
6
University Health Network, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
7
University of Ottawa/Ottawa Hospital Research Institute/President Lung Cancer Canada, Ottawa, ON, Canada
8
Queen Elizabeth II Health Sciences Centre/Dalhousie University, Halifax, NS, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(1), 73-82; https://doi.org/10.3747/co.25.3867
Submission received: 3 November 2017 / Revised: 8 December 2017 / Accepted: 11 January 2018 / Published: 1 February 2018

Abstract

Background: The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (NSCLS) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with NSCLS, as well as for patients progressing after treatment with epidermal growth factor receptor (EGFR) inhibitors, is the standard of care in Canada and many parts of the world. Methods: A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for EGFR, anaplastic lymphoma kinase (ALK), ROS1, BRAF V600 and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and EGFR T790M upon progression. As well, additional exploratory molecules and targets are likely to impact future patient care, including MET exon 14 skipping mutations and whole gene amplification, RET translocations, HER2 (ERBB2) mutations, NTRK, RAS (KRAS and NRAS), as well as TP53. Results: The standard of care must include the incorporation of testing for novel biomarkers as they become available, as it will be difficult for national guidelines to keep pace with technological advances in this area. Conclusions: Canadian patients with NSCLS should be treated equally; the minimum standard of care is defined in this paper.
Keywords: biomarker testing; lung cancer; EGFR; ALK; ROS1; BRAF V600X; MET; PD-L1; Canada biomarker testing; lung cancer; EGFR; ALK; ROS1; BRAF V600X; MET; PD-L1; Canada

Share and Cite

MDPI and ACS Style

Melosky, B.; Blais, N.; Cheema, P.; Couture, C.; Juergens, R.; Kamel-Reid, S.; Tsao, M.-S.; Wheatley-Price, P.; Xu, Z.; Ionescu, D.N. Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Curr. Oncol. 2018, 25, 73-82. https://doi.org/10.3747/co.25.3867

AMA Style

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao M-S, Wheatley-Price P, Xu Z, Ionescu DN. Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology. 2018; 25(1):73-82. https://doi.org/10.3747/co.25.3867

Chicago/Turabian Style

Melosky, B., N. Blais, P. Cheema, C. Couture, R. Juergens, S. Kamel-Reid, M.-S. Tsao, P. Wheatley-Price, Z. Xu, and D.N. Ionescu. 2018. "Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer" Current Oncology 25, no. 1: 73-82. https://doi.org/10.3747/co.25.3867

APA Style

Melosky, B., Blais, N., Cheema, P., Couture, C., Juergens, R., Kamel-Reid, S., Tsao, M. -S., Wheatley-Price, P., Xu, Z., & Ionescu, D. N. (2018). Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology, 25(1), 73-82. https://doi.org/10.3747/co.25.3867

Article Metrics

Back to TopTop